- Home
- RAMP vs HRMY Comparison
RAMP vs HRMY Comparison
Compare RAMP & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- HRMY
- Stock Information
- Founded
- RAMP 2018
- HRMY 2017
- Country
- RAMP United States
- HRMY United States
- Employees
- RAMP N/A
- HRMY N/A
- Industry
- RAMP EDP Services
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- HRMY Health Care
- Exchange
- RAMP Nasdaq
- HRMY Nasdaq
- Market Cap
- RAMP 2.0B
- HRMY 2.0B
- IPO Year
- RAMP 1987
- HRMY 2020
- Fundamental
- Price
- RAMP $32.19
- HRMY $39.05
- Analyst Decision
- RAMP Buy
- HRMY Strong Buy
- Analyst Count
- RAMP 7
- HRMY 8
- Target Price
- RAMP $39.71
- HRMY $55.00
- AVG Volume (30 Days)
- RAMP 499.0K
- HRMY 593.9K
- Earning Date
- RAMP 02-06-2025
- HRMY 02-20-2025
- Dividend Yield
- RAMP N/A
- HRMY N/A
- EPS Growth
- RAMP N/A
- HRMY N/A
- EPS
- RAMP 0.04
- HRMY 2.11
- Revenue
- RAMP $707,165,000.00
- HRMY $681,879,000.00
- Revenue This Year
- RAMP $13.82
- HRMY $24.79
- Revenue Next Year
- RAMP $9.09
- HRMY $19.00
- P/E Ratio
- RAMP $738.15
- HRMY $18.55
- Revenue Growth
- RAMP 13.84
- HRMY 25.83
- 52 Week Low
- RAMP $21.45
- HRMY $28.14
- 52 Week High
- RAMP $42.10
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- RAMP 63.92
- HRMY 71.30
- Support Level
- RAMP $27.99
- HRMY $35.72
- Resistance Level
- RAMP $31.90
- HRMY $37.16
- Average True Range (ATR)
- RAMP 0.80
- HRMY 1.29
- MACD
- RAMP 0.11
- HRMY 0.48
- Stochastic Oscillator
- RAMP 89.94
- HRMY 92.25
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.